Search results
Found 30962 matches for
The Aspirin Esomeprazole Chemoprevention Trial (AspECT) is to our knowledge one of the largest cancer prevention trials using aspirin and acid suppression in the world. In total 2557 patients with a common precancerous change in their oesophagus, called Barrett’s oesophagus, were followed up for an average of 9 years resulting in over 20,000 life-years of follow up. After informed written consent, patients were randomly allocated to four different combinations; Low acid suppression alone, High acid suppression alone, low acid suppression with 300mg aspirin and high acid suppression with 300mg aspirin. We wanted to see if we could prevent progression to local cancer/cancer in-situ (high grade dysplasia), invasive cancer or prevent death by all causes both cancer and non-cancer.
OCTRU Training Bite: GEN-072 Requests for Unplanned Deletions *online*
Wednesday, 20 August 2025, 11am to 11.45am
OCTRU Training Bite: GEN-072 Requests for Unplanned Deletions *online*
Tuesday, 12 August 2025, 2pm to 2.45pm
OCTRU Training Bite: GEN-072 Requests for Unplanned Deletions *online*
Monday, 04 August 2025, 10am to 10.45am
OCTRU Extended Training Bite: Introduction to the Trial Master File (TMF) *online*
Tuesday, 12 August 2025, 10am to 12pm
Trials Expertise Session: Effective planning and management of trial sample collections
Tuesday, 04 November 2025, 10.30am to 11.30am
Trials Expertise Session: The role of a Trial Manager in a Trial Management Group (TMG) *online*
Thursday, 12 June 2025, 10am to 11am
Trials Expertise Session: Communication skills in Clinical Trials for Trial Managers *online*
Wednesday, 26 March 2025, 10am to 11am
Trials Expertise Session: Site Feasibility Questionnaires (SFQ) & Site selection *Hybrid*
Wednesday, 25 June 2025, 11am to 12pm